Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Regulatory Post Marketing Surveillance Study on YAZ

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: September 21, 2009
Last updated: January 19, 2015
Last verified: January 2015
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.

Condition Intervention
Premenstrual Syndrome
Drug: EE20/DRSP (YAZ, BAY86-5300)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Regulatory Post Marketing Surveillance Study on YAZ

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse event collection [ Time Frame: After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days) ]
  • Contraception efficacy [ Time Frame: After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days) ]
  • Drug compliance [ Time Frame: After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days) ]
  • Release of Premenstrual Dysphoric Disorder (PMDD) or acne [ Time Frame: After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days) ]

Secondary Outcome Measures:
  • Number of patients who used YAZ just for contraception [ Time Frame: At initial visit (Day 0) ]
  • Number of patients who used YAZ for PMDD + contraception [ Time Frame: At initial visit (Day 0) ]
  • Number of patients who used YAZ for Acne + contraception [ Time Frame: At initial visit (Day 0) ]

Biospecimen Retention:   None Retained

Enrollment: 770
Study Start Date: July 2009
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: EE20/DRSP (YAZ, BAY86-5300)
Patients under daily life treatment with YAZ according to local drug information.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Korean female who need only contraception or contraception and management of PMDD or contraception and treatment of acne.

Inclusion Criteria:

  • Healthy female subjects

    • requesting contraception
    • suggesting PMDD by Physician who are also requesting contraception
    • with acne who are also requesting contraception
  • Age: 18 - 50 years
  • Women who is prescribed YAZ first, during study period

Exclusion Criteria:

  • Women who are contraindicated based on the label of YAZ

    • Presence or a history of venous or arterial thrombotic/ thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident
    • Presence or history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris)
    • History of migraine with focal neurological symptoms
    • Diabetes mellitus with vascular involvement
    • The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication
    • Pancreatitis or a history thereof if associated with severe hypertriglyceridemia
    • Presence or history of severe hepatic disease as long as liver function values have not returned to normal
    • Severe renal insufficiency or acute renal failure
    • Presence or history of liver tumours (benign or malignant)
    • Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts)
    • Undiagnosed vaginal bleeding
    • Known or suspected pregnancy
    • Hypersensitivity to the active substances or to any of the excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00998257

Korea, Republic of
Many Locations, Korea, Republic of
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00998257     History of Changes
Other Study ID Numbers: 14785
YA0910KR ( Other Identifier: company internal )
YAZ rPMS ( Other Identifier: company internal )
Study First Received: September 21, 2009
Last Updated: January 19, 2015

Keywords provided by Bayer:
Premenstrual Dysphoric Disorder

Additional relevant MeSH terms:
Premenstrual Syndrome
Menstruation Disturbances
Pathologic Processes processed this record on May 22, 2017